Pandora Media Inc (NYSE:P) also said that it’s phasing out its monthly audience metrics, with the final update coming in June, but it will continue to report metrics on a quarterly basis. Pandora Media Inc (NYSE:P) stock opened at $37.92 in last session, and closed at $37.23, while the day range of P stock is $36.57-$38.66.The stock showed a negative weekly performance of -3.27%.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) expects to start crucial phase 3 trials of at least three drugs by the end of this year as well as move 1 to the phase 2 stage in the same period. Operating expenses are expected to increase on this account. Kynamro continues to do well, according to an update by the company. The product is being handled by partner Genzyme. Though the company did not provide any figures on sales revenues, the fact that Genzyme is expanding its sales force, indicates the future potential. Kynamro is currently available in Argentine, Mexico as well as South Korea. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) stock opened at $56.01, in last session and closed at $52.26, by loosed -6.49%. The 52 week range was $15.92-$62.66. Company’s market capitalization is $6.13 billion.
Stock analysts at Leerink Swann upped their target price on shares of Synageva BioPharma Corp. (NASDAQ:GEVA) from $62.00 to $101.00 in a report issued on Tuesday, Analyst Ratings.Net reports. Leerink Swann’s price objective would suggest a potential downside of 4.49% from the stock’s previous close. Synageva BioPharma Corp (NASDAQ:GEVA) stock loosed -7.05% and finished the last session at $98.29. The EPS of the stock remained -3.40.Company’s market capitalization is $3.27 billion.
Puma Biotechnology Inc. (NYSE: PBYI) a development stage biopharmaceutical company announced that results of the Phase II clinical trial of Puma’s investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY2 TRIAL) will be presented in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014 April 5-9 in San Diego California. The presentation entitled “Neratinib plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Efficacy Results from the I-SPY 2 TRIAL” will be included in the session entitled “Clinical Trials Symposium: Biomarker Driven Clinical Trials” which will be held from 10:30 a.m. to 12:30 p.m. PDT on Monday April 7 in Room 29 at the San Diego Convention Center. Puma Biotechnology Inc (NYSE:PBYI) stock opened the session at $120.89, and closed the session at $114.09. The 52 week range of the PBYI stock remained $26.26-$143.65 and the day range was $111.23-$121.02.